RAPT Therapeutics' RPT904 Shows Comparable Efficacy to Xolair in Chronic Hives Trial
核心洞察
RAPT Therapeutics' experimental drug RPT904 demonstrated comparable efficacy and safety to Roche and Novartis' Xolair in treating chronic spontaneous urticaria (搜索) in a 137-patient mid-stage trial conducted in China.
Nearly 46% of patients receiving RPT904 achieved complete symptom resolution at week 16, compared to 33.3% of patients treated with Xolair.
The study tested RPT904 administered at 8-week and 12-week intervals versus Xolair's standard 4-week dosing schedule, potentially offering a more convenient treatment option.
RAPT Therapeutics announced positive results from a mid-stage trial of its experimental drug RPT904 for treating chronic spontaneous urticaria (搜索) (CSU), showing comparable efficacy and safety to the established treatment Xolair from Roche and Novartis. The 137-patient study conducted in China demonstrated that RPT904 could offer a promising alternative for patients suffering from this chronic skin condition.
Trial Design and Patient Population
The study evaluated RPT904 administered at extended dosing intervals of 8 weeks and 12 weeks, compared to Xolair's standard 4-week dosing schedule. The trial included 137 patients with chronic spontaneous urticaria (搜索), also known as chronic hives (搜索), a skin condition characterized by recurring itchy red patches without a known trigger that can persist for months.
Efficacy Results
The trial results showed that nearly 46% of patients treated with RPT904 achieved complete resolution of hive symptoms at week 16, compared to 33.3% of patients receiving Xolair. This represents a notable improvement over the established therapy, suggesting RPT904's potential as an effective treatment option for CSU patients.
Study Limitations and Design
RAPT Therapeutics noted that the study was not designed as a formal non-inferiority trial, and no statistical hypothesis was tested. This limitation means that while the results are encouraging, further studies would be needed to establish definitive comparative efficacy claims.
Market Response
The positive trial results generated significant investor enthusiasm, with RAPT Therapeutics shares rising as much as 90% to $55.64 following the announcement. The stock has demonstrated strong year-to-date performance, with gains of approximately 132% up to the last close before the announcement.
Clinical Significance
Chronic spontaneous urticaria (搜索) represents a significant unmet medical need, as patients often struggle with persistent symptoms that can substantially impact quality of life. The potential for extended dosing intervals with RPT904 could offer improved convenience compared to current treatment options, potentially enhancing patient compliance and treatment outcomes.